中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2014年
13期
24-25
,共2页
恩替卡韦分散片%乙肝肝硬化%代偿期%HBV-DNA%甲状腺激素
恩替卡韋分散片%乙肝肝硬化%代償期%HBV-DNA%甲狀腺激素
은체잡위분산편%을간간경화%대상기%HBV-DNA%갑상선격소
Entecavir dispersible tablets%Hepatitis b induced cirrhosis%Decompensated%HBV-DNA%TSH
目的：观察恩替卡韦治疗代偿期乙肝肝硬化期间患者血清甲状腺激素的变化情况。方法：选取代偿期乙肝肝硬化患者53例，给予恩替卡韦分散片0．5mg口服，1次/d，连续治疗24周，观察比较治疗前后患者血清T3、T4、FT3、FT4、TSH的水平变化。结果：治疗24周所有患者的血清甲状腺激素水平均较治疗前有明显改善，HBV-DNA转阴组患者的血清甲状腺激素水平改善程度比HBV-DNA未转阴组患者更佳（P＜0．05）。结论：代偿期乙肝肝硬化患者给予恩替卡韦抗病毒治疗的同时，可显著改善血清甲状腺激素水平，对乙肝肝硬化治疗具有积极意义。
目的：觀察恩替卡韋治療代償期乙肝肝硬化期間患者血清甲狀腺激素的變化情況。方法：選取代償期乙肝肝硬化患者53例，給予恩替卡韋分散片0．5mg口服，1次/d，連續治療24週，觀察比較治療前後患者血清T3、T4、FT3、FT4、TSH的水平變化。結果：治療24週所有患者的血清甲狀腺激素水平均較治療前有明顯改善，HBV-DNA轉陰組患者的血清甲狀腺激素水平改善程度比HBV-DNA未轉陰組患者更佳（P＜0．05）。結論：代償期乙肝肝硬化患者給予恩替卡韋抗病毒治療的同時，可顯著改善血清甲狀腺激素水平，對乙肝肝硬化治療具有積極意義。
목적：관찰은체잡위치료대상기을간간경화기간환자혈청갑상선격소적변화정황。방법：선취대상기을간간경화환자53례，급여은체잡위분산편0．5mg구복，1차/d，련속치료24주，관찰비교치료전후환자혈청T3、T4、FT3、FT4、TSH적수평변화。결과：치료24주소유환자적혈청갑상선격소수평균교치료전유명현개선，HBV-DNA전음조환자적혈청갑상선격소수평개선정도비HBV-DNA미전음조환자경가（P＜0．05）。결론：대상기을간간경화환자급여은체잡위항병독치료적동시，가현저개선혈청갑상선격소수평，대을간간경화치료구유적겁의의。
Objective:To observe the change of TSH of patients with decompensated hepatitis b induced cirrhosis treated by Entecavir . Methods:53 patients with decompensated hepatitis b induced cirrhosis were chosen and treated by oral Entecavir Dispersible Tablets , 0. 5 mg, once a day.The course of treatment was 24 weeks.The change of T3、T4、FT3、FT4、TSH were compared before and after treatment . Results:The TSH of all patients was improved after 24 weeks treatment .The improvement of TSH of patients which HBV -DNA turned negative was better than the patients which HBV -DNA didn't turn negative (P<0.05).Conclusions:The patients with decompensated hepatitis b induced cirrhosis were treated by Entecavir for antivirus , it could improve the TSH significantly at the same time .It is positive significance for the treatment of patients with Decompensated Hepatitis b Induced cirrhosis .
